Quality of life with ribociclib versus abemaciclib as first-line treatment of HR+/HER2− advanced breast cancer: a matching-adjusted indirect comparison

BACKGROUND: A cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) + endocrine therapy is recommended as first-line treatment for hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) advanced breast cancer (ABC). Quality of life (QoL) is an important endpoint that affec...

Descripción completa

Detalles Bibliográficos
Autores principales: Rugo, Hope S., Harmer, Victoria, O’Shaughnessy, Joyce, Jhaveri, Komal, Tolaney, Sara M., Cardoso, Fatima, Bardia, Aditya, Maheshwari, Vikalp Kumar, Tripathi, Sandeep, Haftchenary, Sina, Pathak, Purnima, Fasching, Peter A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9969464/
https://www.ncbi.nlm.nih.gov/pubmed/36861085
http://dx.doi.org/10.1177/17588359231152843

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9969464/
https://www.ncbi.nlm.nih.gov/pubmed/36861085
http://dx.doi.org/10.1177/17588359231152843

Ejemplares similares